Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Telomir Pharmaceuticals, Inc. ( (TELO) ) is now available.
On June 18, 2025, Telomir Pharmaceuticals announced positive preclinical data for its lead candidate, Telomir-1, demonstrating cellular protective activity in human progeria cell lines. The study showed that Telomir-1 increased cell viability, normalized reactive oxygen species, and restored mitochondrial function, suggesting potential therapeutic benefits for children with HGPS. These findings build on previous studies and support the company’s plans to engage with the FDA for regulatory pathways, including orphan drug designation, as it evaluates multiple rare disease indications for clinical development.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on reversing biological aging and age-related diseases. The company is working on developing treatments for ultra-rare pediatric disorders such as Hutchinson-Gilford Progeria Syndrome (HGPS), which is characterized by rapid biological aging in children.
Average Trading Volume: 200,323
Technical Sentiment Signal: Sell
Current Market Cap: $59.53M
For detailed information about TELO stock, go to TipRanks’ Stock Analysis page.